Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
37.552,16 +113,55 (+0,30%) EUR/USD
1,0704 +0,0048 (+0,45%) Bitcoin EUR
62.021,23 -335,38 (-0,54%) CMC Crypto 200
1.429,93 +15,17 (+1,07%)
Allarity Therapeutics, Inc. (ALLR)
Dopo ore:
| Chiusura precedente | 1,4200 |
| Aperto | 1,4800 |
| Denaro | 1,1900 x 200 |
| Lettera | 1,5100 x 100 |
| Min-Max giorno | 1,3600 - 1,6600 |
| Intervallo di 52 settimane | 1,2700 - 442,4000 |
| Volume | |
| Media Volume | 502.050 |
| Capitalizzazione | 2,763M |
| Beta (5 anni mensile) | 0,24 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -205,2000 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAllarity Therapeutics to Present at Biomarkers Europe 2023
Allarity will present on development of several drug-specific DRP® companion diagnostics, and participate in a panel discussion with speakers from Merck and Roche BOSTON, October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is pleased to announce that the Company has been invited to give a presentati
- GlobeNewswire
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to unselected patients BOSTON (August 30, 2023) — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, announced today the publi
GlobeNewswireAllarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Detsamma Investments Pty. Ltd. trading as “FivepHusion,” an advanced clinical-stage biotechnology company developing Deflexifol™, an optimized all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator l
